Visit the download center to read our exclusive interviews with some of our featured speakers for 2018!

SMi Group is thrilled to announce the 20th Annual Superbugs & Superdrugs Conference in London on 19th – 20th March 2018. As the global threat of antimicrobial resistance continues to develop, it is clear that a global commitment is required in order to tackle the ever-increasing problem of multidrug-resistant bacteria.

This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.

 Join us to learn about various strategies in place to support antimicrobial resistance research & development, evaluate the latest scientific advancements for tackling antimicrobial resistance and consider potential novel candidates and alternatives to anti-microbials.

The event will also focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.


Learn how GARDP are facilitating the research and development on new antibiotics

Hear from The Pew Charitable Trusts about their new digital platform SPARK, allowing researchers to share data, ideas, and insights to spur the discovery of innovative new antibiotics

Discover how Oppliotech is using a systems biology approach to develop antibacterial drugs: through a computational network model to guide the identi?cation of potentiator targets

Examine the latest novel candidates and alternatives to antibiotics including Contrafect’s Lysin Products and Professor Ian Henderson’s research using apheresis

Ensure compliance through regulatory updates on policy and planned revisions to EMA guidance

Previous attendees include:

7i Med Ltd; ACT Surfaces ; Alacrita LLP; Anti-infectives ; Antikor Biopharma; Arsanis Biosciences GmbH; Auspherix Ltd; BARDA; BIOASTER; Blueberry Therapeutics Ltd. ; Cantab Anti-infectives; Cempra Pharmaceuticals; Centauri Therapeutics; Chemical Biology Ventures; Clarivate Analytics; Da Volterra; Drugs for Neglected Diseases initiative (DNDi); dstl (Defence Science and Technology Laboratory); Elsevier; Emergent BioSolutions; Emergent BioSolutions Inc.; European Commision; Evotec; F. Hoffmann-La Roche; F. Hoffmann-La Roche Ltd.; Fidelta Ltd; GOETZPARTNERS CORPORATE FINANCE LIMITED; Karolinska Institute; KWS BioTest; Laboratoire Biodim; Medecins Sans Frontieres; MGB Biopharma; MHRA; Mutabilis S A; Neem Biotech; Nemesis bioscience ; NeoSome Life Sciences, LLC; Northern Antibiotics Ltd.; Nosopharm; Office of Health Economics (OHE); Phico Therapeutics; Phico Therapeutics Ltd; Polyphor Ltd; QuantumDX; Sankio Pharma Gmbh; Spero Therapeutics; St George's, University of London; The Wellcome Trust; Tiber Creek Partners; TNO Pharma; TranScrip Partners; TranScrip Partners LLP; University Hospital of Copenhagen ; University Of Liverpool; University of North Texas Health Science Center; Venaticus Symcel ; VIB; Wellcome Trust;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks: What has happened over the last year and prospects for the future?

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners
View Bio

9:15 GARDP: an alternative model to antibiotic drug development

Jean-Pierre Paccaud

Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
View Bio

  • GARDP is a not-for-profit R&D organisation developing new treatments to tackle drug-resistant bacterial infections, and aiming at delivering them in a responsible, sustainable and accessible manner.
  • Public-private partnerships contributions to fight AMR: collaboration and complementarity.
  • Experimenting alternative business models to deliver innovation.
  • Current programs and deals will be presented. 
  • 9:55 Incentivizing Antibacterial Research and Development

    Christopher Houchens

    Christopher Houchens, Branch Chief, Antibacterials Program, BARDA

    - What is BARDA and why is it interested in AMR
    - How BARDA partners with industry to stimulate innovation in AMR R&D
    - How CARB-X is refilling the preclinical AMR product pipeline

    10:35 Morning Coffee

    11:05 Bacterial cybergenetics to resurrect sensitivity to antibiotics in anti-microbial resistant (AMR) pathogens

    Conrad Lichtenstein

    Conrad Lichtenstein, CSO, Nemesis bioscience
    View Bio

    • “Nemesis Symbiotics” use programmable RNA-guided DNA endonuclease gene editing technology to target antibiotic resistance genes.
    • A single Symbiotic inactivates members of multiple families of resistance genes –so resurrecting sensitivity to antibiotics.
    • Pre-clinical studies show that Transmids, our novel vectors, deliver Symbiotics to bacteria by phage-coat infection and subsequently spread by bacterial conjugation.
    • Symbiotics are biological companion therapeutics to be used together with well-established antibiotics for both therapeutic treatment of infection as well as prophylactic treatment preventing the spread of AMR.

    11:45 Using immune modulation alongside antibiotics to counter multidrug-resistant bacteria

    David Brown

    David Brown, Managing Director and Founder, Alchemy Biomedical Consulting
    View Bio

    • The antibiotic field can arguably learn from oncology where immune modulation used alongside chemotherapy has transformed treatment prospects.
    • Similarly, to beat resistant bacteria, we need to counter the way they usurp our immune defenses to evade antibiotics.
    • Summarising novel ideas on using immune modulation alongside antibiotics to beat resistant species.
    • Suggesting that adding a third component could reduce death rates from sepsis which remain very high even with use of modern antibiotics.

    12:25 Networking Lunch

    13:35 SPARKing New Antibiotic Discovery – the Shared Platform for Antibiotic Research and Knowledge

    Kathy Talkington

    Kathy Talkington, Project Director, Pew charitable trusts
    View Bio

    • The Shared Platform for Antibiotic Research and Knowledge is a groundbreaking and dynamic information-sharing platform.
    • Bringing together curated antibiotic discovery data and cutting-edge analytics to help scientists tackle the scientific barriers blocking antibiotic discovery.
    • While the global threat of antibiotic resistance continues to rise, nearly every antibiotic in use today is based on a discovery from more than 30 years ago.
    • SPARK will focus on the unique challenges of finding and designing antibiotics that can defeat drug-resistant Gram-negative bacteria, which are among the hardest-to-treat superbugs

    14:15 Use of the PasNas platform to enable high quality antibacterial hit finding

    Domingo  Gargallo-Viola

    Domingo Gargallo-Viola, Chief Scientific Officer, ABAC Therapeutics
    View Bio

    • The infectious diseases drug discovery is enormously inefficient. We can not repeat things over and over again. What can we do to change this trend?
    • Disruptive Innovation to control risk factors, improve efficiency and ensure delivery. 
    • New paradigms in infectious diseases, from magic bullet to precision antibacterial agents

    14:55 Afternoon Tea

    15:25 Building a detailed computational network model of cell envelope biogenesis: a systems biology approach to developing antibacterial drugs (potentiators)

    John George

    John George, CSO, Oppilotech
    View Bio

    • Model incorporates the synthesis of key components including LPS, phospholids and peptidoglycan
    • The model is used to guide the identification of potentiator targets– agents that can enhance the activities of existing antibiotics
    • Potentiator programmes derived from model

    16:05 Teaching old cephalosporin dogs new mechanistic tricks against MDR Gram-negative bacteria

    Larry Sutton

    Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
    View Bio

    • Cephalosporin synthetic scaffolding for new mechanisms
     In vitro activity versus WHO critical priority pathogens
    • Comparison to new combination β-lactams
    • In vivo performance

    16:45 Novel virulence factors of Acinetobacter baumannii as targets for antibacterial development

    Daniel  Zurawski

    Daniel Zurawski, Head, Antibacterial Discovery and Development, Walter Reed Army Institute Of Research
    View Bio

    • Over the past 3-4 years, my team has exploited a transposon mutant library to identify targets required for A. baumannii virulence in animal models of infection.
    • Some of these genes/proteins are novel targets on the surface of the bacterium that we are currently developing human monoclonal antibodies against.
    •  We have also identified some targets within the bacterium that could be drug-able.
    • As we learn and test more, we believe the true strength of our research is not a single attack against the bacteria, but rather a combination of multiple drugs/antibodies against different targets to render the bacteria avirulent and cleared by the immune system.

    17:25 Chairman’s Closing Remarks and Close of Day One

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures
    View Bio

    9:10 Highlights from the Traditional and Alternative Antibacterial Pipeline

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures
    View Bio

    • What new therapies can we anticipate?
    • Research challenges
    • Are we asking the right questions?

    9:50 Regulatory considerations for the registration of new antibacterial agents

    Mair Powell

    Mair Powell, Senior clinical assessor, MHRA
    View Bio

    • Ensuring that candidate antibacterial agents with potential to address an unmet need are evaluated in line with regulatory guidance
    • Options for clinical development programmes
    • Importance of the pharmacokinetic-pharmacodynamic relationship 
    • Update on recent guidance and planned revisions to EMA guidance

    10:30 Tackling the current lack of incentives for people working in antimicrobial research and development

    11:10 Morning Coffee

    11:40 Iclaprim: a well differentiated, targeted, potent and rapidly bactericidal antibiotic against multidrug resistant bacteria

    David Huang

    David Huang, Chief Medical Officer, Motif BioSciences
    View Bio

    • Exploring a novel mechanism of action different from any other antibiotic currently in development
    • Positive clinical outcomes among patients with ABSSSI and HAP/VAP through optimizing iclaprim's dose and the concentration at sites of infection
    • Looking into safety data and what lies ahead to achieve FDA and EMA approval

    12:20 Unlocking Reactive Oxygen: A New Generation of Antimicrobials

    Matthew  Dryden

    Matthew Dryden, Chief Scientific Adviser, Matoke Holdings

    • Insight into the Reactive Oxygen mechanism
         o The microbiology
         o Potential formulations
    • Medical need
         o Tackling the World Health Organisation’s most deadly bacteria
    • Navigating the UK regulatory process
    • What’s next for Matoke and Reactive Oxygen

    13:00 Networking Lunch

    14:00 Challenges in Antimicrobial Evaluation of Novel Therapies using Animal Models

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
    View Bio

    • Where to start / What model to use
    • Dose / Regimen – How to choose
    • Test articles with no intrinsic activity
    • How to evaluate combination therapy
    • What does the data tell us?

    14:40 Lysins: Alternative Antimicrobials to Improve Clinical Outcomes Serious Bacterial Infections - CF-301 - A Case Study

    Cara Cassino

    Cara Cassino, Chief Medical Officer, ContraFect
    View Bio

    • CF-301 demonstrates the hallmark features of lysins, including: rapid, targeted bacteriolysis, potent synergy with conventional antibiotics, activity against antibiotic-resistant strains, low propensity for resistance and remarkable biofilm eradication, which make lysins attractive therapeutic candidates for serious bacterial infections.
    • In vivo studies with CF-301 signal the therapeutic potential of lysins boost the efficacy of conventional antibiotics and combat antimicrobial resistance 
    • The ongoing CF-301 clinical development program will help define the place in therapy for ability of lysin therapeutics in the treatment of serious, invasive, biofilm-dependent bacterial infections is being evaluated in clinical development

    15:20 Afternoon Tea

    15:50 C. auris – a difficult to treat, emerging pathogen

    Stephen Barat

    Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    View Bio

    • Brief history of C. auris
    • How C. auris differs from other candida species
    • Experimental models of C. auris
    • New potential treatments

    16:30 Amelioration of multi drug resistant infection by antibody modulation

    Ian Henderson

    Ian Henderson , Professor of Microbial Biology, University Of Birmingham
    View Bio

    • Some individuals overproduce antibody that recognises surface structures on bacteria
    • Such antibody interferes with serum killing of the bacterium
    • Removal of these antibodies by apharesis restores serum killing
    • Restoration  of serum killing is associated with clinical improvement

    17:10 Chairman’s Closing Remarks and Close of Day Two

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures
    View Bio


    Sponsors and Exhibitors

    Official Media Partner



    The Use of Animal Models in Pre-clinical Drug Development

    The Use of Animal Models in Pre-clinical Drug Development

    Copthorne Tara Hotel
    21st March 2018
    London, United Kingdom


    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.



    An Interview with ABAC Therapeutics


    An Interview with Alchemy Biomedical Consulting


    An Interview with Oppilotech


    Sponsors and Exhibitors


    Sponsors and Exhibitors

    For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

    Media Partners

    Microbiology Society

    Official Media Partner

    The Microbiology Society is a membership charity for scientists interested in microbes, their effects and their practical uses. It is one of the largest microbiology societies in Europe with a worldwide membership based in universities, industry, hospitals, research institutes and schools. Our members have a unique depth and breadth of knowledge about the discipline. The Society’s role is to help unlock and harness the potential of that knowledge.

    Global Biodefense

    Official Media Partner

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.

    Media Partners



    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.



    Labiotech.eu is the leading digital media covering the European Biotech industry. It is used by over 55000 people monthly to keep a watch on the business and innovations of biotechnologies.

    Drug Discovery Today


    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.

    Swiss Biotech Association


    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.



    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

    Copybook - Pharmaceutical


    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network

    Inderscience Publishers


    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.

    Biomedicines Journal


    Biomedicines (ISSN 2227-9059) is an open access journal devoted to research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. The aim of Biomedicines is publishing high quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, developmentand ultimately to clinical use. It is published quarterly online by MDPI with rapid publication. Biomedicines is covered by ESCI (Web of Science) and PubMed.



    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.

    Drug Development Technology


    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.



    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

    Bentham Science


    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com

    SciDoc Publishers


    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.



    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.



    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!

    Pharmaceutical Technology


    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.



    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.



    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.



    COMS is a web application for managing delegate registration, payment, paper submission and paper review. Written in Perl and C, with a MySQL database at the back end, it is a comprehensive and powerful, yet easy to use solution for online conference management.



    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.



    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.



    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.




    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.